Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 TresibaⓇ shows lower rate of hypoglycaemia than insulin glargine U100 in SWITCH trials - filed in Q3 2016 SWITCH 1 - type 1 diabetes SWITCH 2 - type 2 diabetes Slide 64 Hypoglycaemic events per 100 PYE Hypoglycaemic TresibaⓇ glargine U100 events per 100 PYE -30%* 3,000 * -11% 300 2,500 250 265 2,000 2,463 200 2,201 1,500 150 * -36% * 1,000 -35% 100 186 -42%* -46% 94 500 50 92 55 429 277 69 9 0 Severe or BG confirmed symptomatic Severe or BG confirmed symptomatic Severe events events Severe or BG confirmed symptomatic events Severe or BG confirmed symptomatic Severe events nocturnal events nocturnal events changing Note: The prevalence of hypoglycaemia is measured during the maintenance period; Blood glucose confirmed hypoglycaemia is defined as <56 mg/dL (<3.1 mmol/L); The confirmatory diabetes secondary endpoint of proportions of subjects experiencing severe hypoglycaemia during the maintenance period did not reach statistical significance in the SWITCH 2 trial. * Statistically significant; BG: Blood glucose; PYE: Patient years exposed novo nordisk

View entire presentation